费用分担与纳洛酮处方调配的关联
本研究为横断面回归断点分析,利用商业保险和Medicare计划在每年1月1日重置免赔额的特点,纳入2020-2021年IQVIA Formulary Impact Analyzer数据库中纳洛酮鼻喷雾剂理赔数据(覆盖美国药房63%的处方),分析2021年1月1日前60天至后59天的理赔。结果显示,2021年1月1日商业保险患者每次理赔平均费用分担增加15.0美元(95%CI 13.8-16.2),处方放弃概率增加4.7个百分点(95%CI 3.2-6.2);Medicare患者平均费用分担增加12.3美元(95%CI 10.9-13.6),处方放弃概率增加2.8个百分点(95%CI 1.6-4.1)。模糊回归断点分析提示,计划将纳洛酮费用分担增加10美元,商业保险和Medicare患者的处方放弃概率分别增加3.1个百分点(95%CI 2.2-4.1)和2.3个百分点(95%CI 1.4-3.2)。作者认为取消费用分担可能与纳洛酮调配增加相关。
要点
- 2021年1月1日免赔额重置时,商业保险患者纳洛酮每次理赔平均费用分担增加15.0美元(95%CI 13.8-16.2),处方放弃概率增加4.7个百分点(95%CI 3.2-6.2)。
- 同日Medicare患者纳洛酮每次理赔平均费用分担增加12.3美元(95%CI 10.9-13.6),处方放弃概率增加2.8个百分点(95%CI 1.6-4.1)。
- 模糊回归断点分析提示,费用分担增加10美元与商业保险患者处方放弃概率增加3.1个百分点(95%CI 2.2-4.1)、Medicare患者增加2.3个百分点(95%CI 1.4-3.2)相关。
- 分析纳入商业保险患者71 306例(73 311次理赔)和Medicare患者101 706例(106 076次理赔),女性分别占56.1%和60.4%。
- 作者认为取消费用分担可能与商业保险和Medicare患者纳洛酮调配增加相关。
适用人群与场景
- 商业保险患者和Medicare患者中纳洛酮鼻喷雾剂的理赔,数据来自2020-2021年IQVIA Formulary Impact Analyzer数据库(覆盖美国药房63%的处方)。
- 分析窗口为2021年1月1日前60天至后59天的理赔。
研究设计与关键结果
- 研究设计:横断面回归断点分析,利用商业保险和Medicare计划免赔额在年初重置的特点。
- 样本量:商业保险患者71 306例(73 311次纳洛酮理赔),Medicare患者101 706例(106 076次理赔);女性分别占56.1%和60.4%。
- 主要终点:2021年1月1日商业保险患者每次理赔平均费用分担增加15.0美元(95%CI 13.8-16.2),处方放弃概率增加4.7个百分点(95%CI 3.2-6.2);Medicare患者平均费用分担增加12.3美元(95%CI 10.9-13.6),处方放弃概率增加2.8个百分点(95%CI 1.6-4.1)。
- 模糊回归断点分析:费用分担增加10美元与商业保险患者处方放弃概率增加3.1个百分点(95%CI 2.2-4.1)相关,与Medicare患者增加2.3个百分点(95%CI 1.4-3.2)相关。
证据类型、等级与局限
- 证据类型:横断面回归断点分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为取消费用分担可能与商业保险和Medicare患者纳洛酮调配增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Increasing access to naloxone (an opioid antagonist that can reverse overdose) could slow the US opioid epidemic. Prior studies suggest cost sharing may be a barrier to dispensing of naloxone prescriptions, but these studies were limited by their cross-sectional designs and use of databases that do not capture prescriptions that are not filled (abandoned).
OBJECTIVE: To evaluate the association between cost sharing and naloxone prescription abandonment (nondispensing of naloxone prescriptions).
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional, regression discontinuity analysis exploited the fact that deductibles typically reset at the beginning of the year in commercial and Medicare plans. The included data were derived from the 2020-2021 IQVIA Formulary Impact Analyzer (a pharmacy transactions database that represents 63% of prescriptions at US pharmacies). The analysis included claims for naloxone nasal spray among commercially insured patients and Medicare patients that occurred during the 60 days before January 1, 2021, through 59 days after January 1, 2021.
EXPOSURE: Cost sharing, which is defined as the amount patients would have to pay to fill prescriptions.
MAIN OUTCOMES AND MEASURES: Local linear regression models were used to assess for abrupt changes in cost sharing and the probability of prescription abandonment on January 1, 2021. To estimate the association between cost sharing and prescription abandonment, a fuzzy regression discontinuity analysis was conducted.
RESULTS: These analyses included naloxone claims for 71 306 commercially insured patients and 101 706 Medicare patients (40 019 [56.1%] and 61 410 [60.4%], respectively, were female). The commercially insured patients and Medicare patients accounted for 73 311 and 106 076 naloxone claims, respectively. On January 1, 2021, the mean cost sharing per claim increased by $15.0 (95% CI, $13.8-$16.2) for commercially insured patients and increased by $12.3 (95% CI, $10.9-$13.6) for Medicare patients and the probability of abandonment increased by 4.7 (95% CI, 3.2-6.2) percentage points and 2.8 (95% CI, 1.6-4.1) percentage points, respectively. The results from the fuzzy regression discontinuity analysis suggest a decision by commercial and Medicare plans to increase naloxone cost sharing by $10 would be associated with percentage-point increases of 3.1 (95% CI, 2.2-4.1) and 2.3 (95% CI, 1.4-3.2), respectively, in the probability of abandonment.
CONCLUSIONS: The elimination of cost sharing might be associated with increased naloxone dispensing to commercially insured and Medicare patients.
参考来源
- Chua KP, Conti RM, Lagisetty P, et al. Association Between Cost Sharing and Naloxone Prescription Dispensing. JAMA. 2024. PMID: 38869887. doi:10.1001/jama.2024.8378
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。